Last year in the UK over 60,000 cancer patients enrolled on clinical trials aimed at improving cancer treatments and making them available to all.
A trial looking at ponatinib for people with newly diagnosed chronic myeloid leukaemia (EPIC)
This trial was looking at ponatinib for people with newly diagnosed chronic myeloid leukaemia (CML) that is Philadelphia chromosome positive. It was for people whose CML was stable and developing slowly (chronic phase).
Most people with CML have a change (
Ponatinib is also a biological therapy that is a cancer growth blocker. It works in a very similar way to imatinib.
We knew from research that ponatinib could work for people with CML that had come back while having treatment with other cancer growth blockers, or after having had treatment with them. The researchers thought that it may work well for newly diagnosed people who had not had treatment.
The aims of this trial were to find out
- How well ponatinib works for newly diagnosed people with CML
- How safe ponatinib is for these people
- How ponatinib affects their
quality of life
Summary of results
This trial was stopped early. The UK trial team have told us they don’t expect there to be results available.
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Richard Clark
ARIAD Pharmaceuticals Inc
NIHR Clinical Research Network: Cancer